Featured Insight
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Poster Presentation: San Antonio Breast Cancer Symposium (SABCS) 2023
Gilead Sciences, Inc. will present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023 supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients. Precision's research with Gilead Sciences on "Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making" will be presented during Poster Session 1: Poster # PO1-10-06 on Wednesday, Dec. 6 at 12:00 PM. Co-authored by Meaghan Roach, Rozanne Wilson, Suepattra May-Slater, Melissa Maravic and Emily Freeman.
Short Courses: ISPOR EU 2023
Precision will be at ISPOR Europe November 12-15, 2023. Don't miss our two Short Courses.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Webinar: Quantifying Health Equity Impact of Innovative Health Care Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join PRECISIONheor for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Virtual ISPOR Europe 2021
Planning on attending Virtual ISPOR EU 30 November - 3 December? PRECISIONheor is excited to be participating and will be presenting a number of insightful posters and presentations.
Featured Expert: Meena Venkatachalam
This month PRECISIONheor would like to highlight the work and expertise of Senior Director Meena Venkatachalam.
Cutting Edge Conversations: Value, Access and Evidence – Biotech Market Access
Don't miss PRECISIONheor's Sajjad Raza in this on-demand webinar, hosted by Scientist.com and HealthEconomics.com, as part of their Cutting Edge Conversations series.
The Complementary Relationship Between Quantitative and Qualitative Research Methods in Enhancing Understanding of Treatment Decisions, Outcomes, and Value Assessment
Quantitative studies are the gold standard for establishing causality and drawing conclusions that can be generalized beyond the population studied. However, quantitative research methods also often lack contextual considerations and perspectives that can be further informed by qualitative approaches.
PRECISIONheor Featured Rare Disease Publications
The high costs often associated with treatments for rare diseases can make it challenging for patients to gain access to these life-changing therapies. PRECISIONheor experts have led research in a number of innovative studies on rare diseases to help get these treatments into the hands of the patients that need them the most.
Featured Expert: Ivar Jensen
This month PRECISIONheor would like to highlight the work and expertise of Senior Director Ivar Jensen.
The role of COVID-19 antibody testing for employers
As employers consider including COVID-19 testing as part of their reopening plans, Precision experts Jacquelyn Chou, Caroline Huber and Jennifer Millard discuss the two key issues that must be resolved before antibody testing can be truly useful for an employer.
What can Linux and Mozilla teach ICER about how to do drug value assessments?
Precision's Jason Shafrin discusses the four major challenges to ICER's approach to value-based price recommendations, and how an open source approach could overcome these challenges.
CAR-T therapy and historical trends in effectiveness and cost–effectiveness of oncology treatments
CAR-T therapy breaks a pattern of stagnant efficacy growth in pharmaceutical innovation. A new CAR-T therapy study demonstrates significantly greater incremental effectiveness and similar cost–effectiveness to previous anticancer treatments.
Drug Pricing and the Broader Quality of Life
By limiting the benefits included in its model and inappropriately valuing these health benefits, ICER risks mispricing innovative health therapies and disincentivizing investments in research and development.
How development of gene therapies impact decisions on their place in therapy
In this article, we explore critical factors in the development of gene therapies, including trial management, accelerated approval pathways, and companion diagnostic development and its coordination with therapeutic development.
Novel value measures and European HTA: Implications for pharma/device HEOR
The term "value" may be thought of as "benefit" which, in turn, triggers a discussion on the opportunity cost of other forgone benefits. New cost-effectiveness modeling methods are required to accommodate the novel sources of value.
